Purification of Influenza Virus Polypeptide Antigens and Studies of Their Immunogenicity and Toxicity
Annual progress rept. 31 Jul 1975-1 Aug 1976
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK
Pagination or Media Count:
Continued development of an infection-permissive neuraminidase- specific vaccine has proceeded. Such a vaccine may be produced either by tailor- making a recombinant virus containing the neuraminidase of the current subtype of influenza virus coupled with an irrelevant hemagglutinin or by isolation of the neuraminidase directly from the virus. Vaccine trials have compared the immune response of a neuraminidase-specific vaccine employing the recombinant X- 38 Heq1N2 with that of a conventional bispecific vaccine, X-37 H3N2. A superior antibody response to neuraminidase was observed when the enzyme was coupled with the irrelevant hemagglutinin in the X-38 vaccine as compared with the conventional vaccine. An unexpected finding was the induction of anti-H3 heterotypic antibody by the X-38 vaccine possessing the irrelevant hemagglutinin. Techniques for viral protein purification have been improved and have shown that hemagglutinin as a dimer is immunogenic.
- Medicine and Medical Research